Pediatric high-grade gliomas: Research reveals effective targeting with avapritinib
Pediatric high-grade gliomas, particularly H3K27M diffuse midline gliomas (DMG), are aggressive malignant brain tumors with a poor prognosis. Previous research suggests that platelet-derived growth ...
MPR5h
Molecular Residual Disease Analysis May Predict Disease Recurrence After Lung Cancer Resection
Molecular residual disease precedes DFS events in patients receiving osimertinib, placebo; most events occur after osimertinib discontinuation or completion.
News Medical on MSN15h
Study identifies PDGFRA as a potential target for pediatric high-grade gliomas
Pediatric high-grade gliomas, particularly H3K27M diffuse midline gliomas (DMG), are aggressive malignant brain tumors with a poor prognosis.
Fierce Pharma1d
FDA calls out 'particularly concerning' claims on HCP site for Taiho's Lytgobi
Lytgobi is an FGFR inhibitor that received accelerated approval in 2022 to treat adults with previously treated, unresectable ...
Medscape1d
Surgical Delay Linked to Higher Mortality Risk in HR+/HER2− Breast Cancer
Researchers conducted a retrospective cohort study of 34,248 women diagnosed with locoregional breast cancer who received ...
J&J says Rybrevant/Lazcluze outperforms osimertinib OS in Phase 3 study
Johnson & Johnson announced results for the “gold standard endpoint in cancer treatment” of overall survival from the Phase 3 ...
News Medical on MSN17h
Scientists uncover rare gene variants that help people live past 100
Researchers studying over 2,000 Ashkenazi Jewish centenarians uncovered two rare IGF-1 gene variants linked to exceptional ...
Pharmaceutical Technology on MSN2d
Sermonix and Regor to enhance breast cancer treatment options
The partnership is expected to yield treatments that demonstrate efficacy and offer improved quality of life and tolerability ...